>欧洲 Kirsten 大鼠肉瘤 (KRAS) 市场，按产品（试剂和试剂盒、分析仪、消耗品）、癌症类型（肺癌、结直肠癌、胰腺癌、乳腺癌、前列腺癌、宫颈癌、皮肤癌、肾癌、血癌等）、年龄组（成人、儿童）、应用（疾病诊断、预测、药物发现和开发治疗方法/预后、分子诊断开发、研究与开发、个性化医疗等）、最终用户（诊断实验室、医院、制药和生物技术公司、肿瘤专科诊所、学术和癌症研究机构等）、分销渠道（直接招标、零售销售、第三方分销商）、国家（德国、法国、英国、意大利、俄罗斯、西班牙、瑞士、荷兰、土耳其、比利时和欧洲其他地区）行业趋势和预测到 2028 年
市场分析和洞察：欧洲克尔斯滕大鼠肉瘤 (KRAS) 市场
预计欧洲 Kirsten 大鼠肉瘤 (KRAS) 市场将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场的复合年增长率为 11.8%，预计到 2028 年将达到 6.6272 亿美元。SARS CoV-2 流行率的增加、诊断测试的批准率的提高是预测期内推动市场发展的主要驱动力。
RAS 蛋白最初属于 Harvey 和 Kirsten 大鼠肉瘤病毒的致癌产物。三种同源基因编码哺乳动物 RAS 蛋白。Harvey Ras 病毒的原癌基因 (H-ras)、Kirsten Ras 病毒的原癌基因 (K-Ras) 和神经 Ras (N-ras)。这三种形式的 RAS 基因存在于不同的哺乳动物人类标本中。在人类神经母细胞瘤和纤维肉瘤细胞系中发现了另一种转化基因，后来被确定为 RAS 基因家族的第三个功能成员。
然而，治疗副作用、未满足的需求、产品召回以及实验室对检测高成本诊断的要求不断提高等因素阻碍了 Kirsten 大鼠肉瘤 (KRAS) 市场的发展。另一方面，即将到来的针对性治疗以及市场参与者之间日益增多的伙伴关系和合作以及对癌症研究的资金增加为 Kirsten 大鼠肉瘤 (KRAS) 市场提供了机遇。缺乏熟练的专业知识和政府对 Kirsten 大鼠肉瘤 (KRAS) 药物开发的严格监管是市场面临的挑战。
这份 Kristen 大鼠肉瘤 (KRAS) 市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入来源、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
克尔斯滕大鼠肉瘤 (KRAS) 市场范围和市场规模
克尔斯滕大鼠肉瘤 (KRAS) 市场根据产品、癌症类型、年龄组、应用、最终用户和分销渠道分为六个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据产品，Kirsten 大鼠肉瘤 (KRAS) 市场细分为分析仪、试剂和试剂盒、耗材。2021 年，试剂和试剂盒部分将主导 Kirsten 大鼠肉瘤 (KRAS) 市场，因为 Kirsten 肉瘤病例增加、在更短时间内获得便捷结果、癌症患者人数增加以及快速诊断问题需求增加预计将主导市场。
- 根据癌症类型，克尔斯滕大鼠肉瘤 (KRAS) 市场细分为乳腺癌、结直肠癌、胰腺癌、肺癌、宫颈癌、前列腺癌、皮肤癌、血癌、肾癌、卵巢癌等。2021 年，肺癌细分市场将主导克尔斯滕大鼠肉瘤 (KRAS) 市场，因为肺癌患病率增加、吸烟者数量增加、不健康的生活方式、诊断仪器的可用性预计将主导市场。
- 根据年龄组，Kirsten 大鼠肉瘤 (KRAS) 市场分为儿童和成人。2021 年，成人群体将主导 Kirsten 大鼠肉瘤 (KRAS) 市场，因为亚太地区患乳腺癌的女性患者增加，吸烟者和腺癌患者的增加预计将主导市场。
- 根据应用，克尔斯滕大鼠肉瘤 (KRAS) 市场细分为分子诊断开发、疾病诊断、药物发现和开发、个性化医疗、预测、研究和开发、治疗方法/预后等。2021 年，疾病诊断领域预计将在克尔斯滕大鼠肉瘤 (KRAS) 市场占据主导地位，因为 KRAS 病例增加，体外诊断和伴随诊断的需求增加，预计这些领域将占据市场主导地位。
- 根据最终用户，Kirsten 大鼠肉瘤 (KRAS) 市场细分为学术和癌症研究机构、诊断实验室、医院、肿瘤专科诊所、制药和生物技术公司等。2021 年，由于存在多种癌症治疗和研究设施，预计诊断实验室将主导市场，健康报酬政策、及时诊断和治疗结果预计将主导市场。
- 根据分销渠道，Kirsten 大鼠肉瘤 (KRAS) 市场分为直接招标、零售和第三方分销商。由于市场供应商的增加，预计 2021 年直接招标部分将主导 Kirsten 大鼠肉瘤 (KRAS) 市场。
欧洲克尔斯滕大鼠肉瘤 (KRAS) 市场国家级分析
对欧洲 Kirsten 大鼠肉瘤 (KRAS) 市场进行分析，并按上述类型和配置提供市场规模信息。
欧洲克尔斯滕大鼠肉瘤 (KRAS) 市场报告涵盖的国家包括德国、英国、法国、意大利、西班牙、俄罗斯、荷兰、瑞士、比利时、土耳其和欧洲其他地区。
由于对拭子检测试剂盒开发的投资不断增加，预计欧洲将主导市场。由于对研发和新产品渗透的投资增加，德国在市场上占据主导地位。由于 Thermofisher Scientific Inc.、Biocartis 等主要公司进入市场，预计英国将在 2021 年至 2028 年的预测期内以最有希望的增长率增长，这些公司正在投资开发有利于获得高精度和最短周转时间的检测试剂盒。然而，由于对研发和新产品渗透的投资增加，法国占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
特定人群中 KRAS 突变风险较高，欧洲制药公司与诊断公司之间的合作Kirsten 大鼠肉瘤 (KRAS) 市场正在为 Kirsten 大鼠肉瘤 (KRAS) 市场的参与者创造新的机会
Kirsten 大鼠肉瘤 (KRAS) 市场还为您提供每个国家/地区特定行业增长的详细市场分析，包括检测试剂盒销售、KRAS 检测试剂盒发展的影响 以及监管环境的变化及其对 Kirsten 大鼠肉瘤 (KRAS) 市场的支持。数据涵盖 2010 年至 2018 年的历史时期。
竞争格局和克尔斯滕大鼠肉瘤 (KRAS) 市场份额分析
Kirsten 大鼠肉瘤 (KRAS) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对 Kirsten 大鼠肉瘤 (KRAS) 市场的关注有关。
在欧洲 Kirsten 大鼠肉瘤 (KRAS) 市场开展业务的主要公司包括 Thermo Fisher Scientific Inc.、F. Hoffmann-La Roche Ltd、Biocartis、Illumina, Inc.、Merck KGaA、Abbott、QIAGEN、Agilent Technologies, Inc. 等。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。
全球各地的公司也发起了许多产品的推出和收购，这也加速了克尔斯滕大鼠肉瘤 (KRAS) 市场的发展。
例如，
- 2021 年 1 月，默克集团宣布收购了总部位于德国汉堡的领先公司 AmpTec，这将增强其 rRNA 制造能力并将其交付给客户用于诊断和疫苗生产，并将增加该公司从诊断部门的收入。
- 2020 年 1 月，QIAGEN 和 Amgen Inc. 宣布建立战略合作关系，分别开发基于血液和组织的伴随诊断 (CDx)，用于研究癌症治疗药物 AMG 510（Sotoranib）。AMG 510 是首个进入临床研究的 KRASG12C 抑制剂，用于研究多种肿瘤类型的治疗。这一进展将增加需求，并有助于诊断各种癌症。
市场参与者的合作、合资和其他策略正在增强公司在 Kirsten 大鼠肉瘤 (KRAS) 市场的市场，这也为组织改善其在 Kirsten 大鼠肉瘤 (KRAS) 市场的供应提供了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 EPIDERMILOGY
6 PESTEL ANALYSIS
7 PORTERS FIVE
8 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: REGULATORY FRAMEWORK
8.1 THE U.S. REGULATORY SCENARIO FOR KIRSTEN RAT SARCOMA (KRAS)
8.2 CANADA REGULATORY SCENARIO FOR KIRSTEN RAT SARCOMA (KRAS)
8.3 EUROPE REGULATORY GUIDANCE FOR KRISTEN RAT SARCOMA (KRAS)
8.4 JAPAN REGULATORY GUIDANCE FOR KIRSTEN RAT SARCOMA (KRAS)
8.5 AUSTRALIA REGULATORY SCENARIO FOR KIRSTEN RAT SARCOMA (KRAS)
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 GROWING PREVALENCE OF CANCER
9.1.2 INCREASING R&D INVESTMENT
9.1.3 HIGH FREQUENCY OF KIRSTEN RAT SARCOMA (KRAS) MUTATION
9.2 RISING SHARE OF AGING POPULATION
9.2.1 PENETRATION OF NOVEL PRODUCTS
9.3 RESTRAINTS
9.3.1 HIGH COST OF PRODUCTS
9.3.2 PRODUCT RECALL IN RECENT PAST
9.3.3 LIMITATION OF KIRSTEN RAT SARCOMA (KRAS) MUTATION TESTING
9.3.4 ADVANCED LABORATORY REQUIREMENT
9.4 OPPORTUNITIES
9.4.1 INCREASING FUNDING FOR CANCER RESEARCH
9.4.2 COLLABORATION BETWEEN PHARMA AND DIAGNOSTIC COMPANIES
9.4.3 HIGH RISK OF KIRSTEN RAT SARCOMA (KRAS) MUTATION IN SPECIFIC POPULATION
9.5 CHALLENGES
9.5.1 LACK OF AWARENESS AND DEARTH OF EXPERTISE
9.5.2 HUGE UNMET MEDICAL NEED FOR KIRSTEN RAT SARCOMA (KRAS)
10 IMPACT OF COVID-19 ON THE EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT OF SUPPLY
10.4 STRATEGIC DECISIONS BY MANUFACTURERS
10.5 CONCLUSION
11 EUROPE KIRSTEN RAT SARCOMA (KRAS) (KRAS) MARKET (KRAS) MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 REAGENTS AND KITS
11.2.1 PCR TEST KITS
11.2.2 LIQUID BIOPSY PANELS
11.2.3 KRAS MONOCLONAL ANTIBODY
11.2.4 OTHERS
11.3 ANALYZERS
11.4 CONSUMABLES
11.5 CAPILLARY ELECTROPHORESIS POLYMERS
11.6 COLUMNS
11.7 BUFFERS
11.8 ENZYMES
11.9 DNA SIZE MARKER
11.1 MAGNET PLATES
11.11 COLLECTION TUBES
11.12 OTHERS
12 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE
12.1 OVERVIEW
12.2 LUNG CANCER
12.3 COLORECTAL CANCER
12.4 PANCREATIC CANCER
12.5 BREAST CANCER
12.6 PROSTATE CANCER
12.7 CERVICAL CANCER
12.8 SKIN CANCER
12.9 KIDNEY CANCER
12.1 BLOOD CANCER
12.11 OTHERS
13 EUROPE KIRSTEN RAT SARCOMA (KRAS) (KRAS) MARKET (KRAS)TREATMENT MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULTS
13.3 PEDIATRIC
14 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 DISEASE DIAGNOSTICS
14.3 PREDICTIVE
14.4 DRUG DISCOVERY AND DEVELOPMENT
14.5 THERAPEUTIC APPROACH OR PROGNOSTICS
14.6 DEVELOPMENT OF MOLECULAR DIAGNOSTICS
14.7 RESEARCH AND DEVELOPMENT
14.8 PERSONALISED MEDICINE
14.9 OTHERS
15 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER
15.1 OVERVIEW
15.2 DIAGNOSTIC LABORATORIES
15.3 HOSPITALS
15.4 PHARMA AND BIOTECH COMPANIES
15.5 ONCOLOGY SPECIALITY CLINICS
15.6 ACADEMIC AND CANCER RESEARCH INSTITUTES
15.7 OTHERS
16 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.4 THIRD PARTY DISTRIBUTOR
17 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET BY COUNTRY
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 RUSSIA
17.1.6 SPAIN
17.1.7 SWITZERLAND
17.1.8 NETHERLANDS
17.1.9 TURKEY
17.1.10 BELGIUM
17.1.11 REST OF EUROPE
18 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 THERMO FISHER SCIENTIFIC INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE FINANCIALS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENTS
20.2 F.HOFFMANN-LA ROCHE LTD
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENTS
20.3 BIOCARTIS
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE FINANCIALS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 ILLUMINA, INC
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE FINANCIALS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 MERCK KGAA
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 0PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 ABBOTT
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENT
20.7 QIAGEN
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 ALIGENT TECHNOLOGIES, INC.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENTS
20.9 AMOY DIAGNOSTICS CO., LTD.
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT S
20.1 AGENA BIOSCIENCES, INC
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 BIOTYPE GMBH
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 CENTOGENE N.V.
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENTS
20.13 DIACARTA
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENTS
20.14 ENTROGEN, INC.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 MIRADX
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 PANAGENE
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 PROTEINTECH GROUP, INC
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.18 SYSMEX INOSTICS
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.19 TAKARA BIO, INC
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE FINANCIALS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 VIENNALAB DIAGNOSTICS GMBH
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 BELOW MENTIONED TABLE SHOWS THE PRICE OF KIRSTEN RAT SARCOMA (KRAS) ANTIBODIES AND VARIOUS OTHER DETECTION KITS THAT ARE SUPPLIED BY MAJOR MARKET PLAYERS:
TABLE 2 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 3 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 4 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 5 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 6 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 7 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 8 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 9 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 10 EUROPE KRISTEN RAT SARCOMA (KRAS) MARKET, COUNTRY, 2019-2028 (USD MILLION)
TABLE 11 EUROPE KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 12 EUROPE REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 13 EUROPE CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 14 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 15 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 16 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 17 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 18 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 19 GERMANY KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 20 GERMANY REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 21 GERMANY CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 22 GERMANY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 23 GERMANY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 24 GERMANY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 25 GERMANY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 26 GERMANY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 27 FRANCE KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 28 FRANCE REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 29 FRANCE CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 30 FRANCE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 31 FRANCE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 32 FRANCE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 33 FRANCE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 34 FRANCE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 35 U.K. KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 36 U.K. REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 37 U.K. CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 38 U.K. KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 39 U.K. KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 40 U.K. KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 41 U.K. KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 42 U.K. KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 43 ITALY KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 44 ITALY REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 45 ITALY CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 46 ITALY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 47 ITALY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 48 ITALY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 49 ITALY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 50 ITALY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 51 RUSSIA KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 52 RUSSIA REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 53 RUSSIA CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 54 RUSSIA KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 55 RUSSIA KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 56 RUSSIA KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 57 RUSSIA KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 58 RUSSIA KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 59 SPAIN KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 60 SPAIN REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 61 SPAIN CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 62 SPAIN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 63 SPAIN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 64 SPAIN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 65 SPAIN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 66 SPAIN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 67 SWITZERLAND KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 68 SWITZERLAND REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 69 SWITZERLAND CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 70 SWITZERLAND KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 71 SWITZERLAND KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 72 SWITZERLAND KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 73 SWITZERLAND KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 74 SWITZERLAND KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 75 NETHERLANDS KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 76 NETHERLANDS REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 77 NETHERLANDS CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 78 NETHERLANDS KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 79 NETHERLANDS KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 80 NETHERLANDS KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 81 NETHERLANDS KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 82 NETHERLANDS KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 83 TURKEY KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 84 TURKEY REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 85 TURKEY CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 86 TURKEY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 87 TURKEY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 88 TURKEY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 89 TURKEY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 90 TURKEY KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 91 BELGIUM KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
TABLE 92 BELGIUM REAGENTS & KITS IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 93 BELGIUM CONSUMABLES IN KIRSTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT 2019-2028 (USD MILLION)
TABLE 94 BELGIUM KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 2019-2028 (USD MILLION)
TABLE 95 BELGIUM KIRSTEN RAT SARCOMA (KRAS) MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 96 BELGIUM KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 2019-2028 (USD MILLION)
TABLE 97 BELGIUM KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 98 BELGIUM KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 99 REST OF EUROPE KRISTEN RAT SARCOMA (KRAS) MARKET, BY PRODUCT, 2019-2028 (USD MILLION )
图片列表
LIST OF FIGURES
FIGURE 1 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: SEGMENTATION
FIGURE 2 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CANCER ASSOCIATED WITH KRAS MUTATION WORLDWIDE, INCREASED INVESTMENT IN R&D AND PENETRATION OF NOVEL KRAS DIAGNOSTIC PRODUCTS IS EXPECTED TO DRIVE THE EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 REAGENTS & KITS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET AND IS ALSO EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 EUROPE KIRSTEN RAT SARCOMA (KRAS) MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET
FIGURE 16 NUMBER OF NEW CANCER CASES IN 2018 FOR ALL AGES
FIGURE 17 BELOW CHART SHOWS THE PREVALENCE OF PANCREATIC CANCER IN THE U.S. REGION FROM 2003-2017:
FIGURE 18 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY PRODUCT, 2020
FIGURE 19 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY PRODUCT, 2020-2028 (USD MILLION)
FIGURE 20 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 21 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 22 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY CANCER TYPE, 2020
FIGURE 23 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY CANCER TYPE , 2020-2028 (USD MILLION)
FIGURE 24 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY CANCER TYPE, CAGR (2021-2028)
FIGURE 25 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 26 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY AGE GROUP, 2020
FIGURE 27 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY AGE GROUP 2020-2028 (USD MILLION)
FIGURE 28 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKETT: BY AGE GROUP, CAGR (2021-2028)
FIGURE 29 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY APPLICATION, 2020
FIGURE 31 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY APPLICATION 2020-2028 (USD MILLION)
FIGURE 32 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 33 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 34 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY END USER, 2020
FIGURE 35 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY END USER 2020-2028 (USD MILLION)
FIGURE 36 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY END USER, CAGR (2021-2028)
FIGURE 37 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 39 EUROPE KIRSTEN RAT SARCOMA (KRAS)MARKET: BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
FIGURE 40 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 41 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 EUROPE KRISTEN RAT SARCOMA (KRAS) MARKET: SNAPSHOT (2020)
FIGURE 43 EUROPE KRISTEN RAT SARCOMA (KRAS) MARKET: BY COUNTRY (2020)
FIGURE 44 EUROPE KRISTEN RAT SARCOMA (KRAS) MARKET: BY COUNTRY (2021 & 2028
FIGURE 45 EUROPE KRISTEN RAT SARCOMA (KRAS) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 EUROPE KRISTEN RAT SARCOMA (KRAS) MARKET: BY PRODUCT TYPE (2021-2028)
FIGURE 47 EUROPE KRISTEN RAT SARCOMA (KRAS) MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
